Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors

Clinical trial NCT06126406 · RECRUITING

Trial details

NCT number: NCT06126406
Sponsor: Chongqing Precision Biotech Co., Ltd
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Gastric Cancer Colon Cancer Rectal Cancer Breast Cancer Lung Cancer Esophagus Cancer Cholangiocarcinoma Pancreas Cancer

Start date: 2023-11-06
Primary completion: 2025-12-31
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.